Fig. 2
Blocking GRP and GRPR enhances survival after influenza infection. a WT C57BL/6J mice were infected with mouse-adapted influenza strain PR8 (LD90; ~7500 TCID50). Mice received vehicle (saline + 0.096% DMSO) or GRP inhibitor (NSC77427; 20 μM, 100 μl i.v./mouse) daily from day 2 to day 6 post-infection. Survival was monitored for 14 days. Data shown are combined results of three assays (5 mice/treatment group/experiment). b WT C57BL/6J mice were infected as described in a. Mice received either control IgG or a highly specific anti-GRP IgG (100 μg; 100 μl i.v./mouse) on days 2 and day 4 post-PR8 infection. Survival was monitored as in a. Data shown are combined results of two assays (5 mice/treatment group/experiment). c WT C57BL/6J mice were infected as described in a. Mice received vehicle (saline) or GRPR antagonist (BW2258U89; 20 μM, 100 μl i.v./mouse). Survival was monitored as in a. Data shown are combined results of two assays (5 mice/treatment group/experiment)
